Salarius Pharmaceuticals ... (SLRX)
1.04
0.00 (0.00%)
At close: Mar 04, 2025, 3:58 PM
1.04
0.00%
After-hours: Mar 04, 2025, 04:05 PM EST
No 1D chart data available
| Bid | 0.96 |
| Market Cap | 1.65M |
| Revenue (ttm) | 22.1K |
| Net Income (ttm) | -6.17M |
| EPS (ttm) | -5.05 |
| PE Ratio (ttm) | -0.21 |
| Forward PE | -0.26 |
| Analyst | n/a |
| Ask | 1.06 |
| Volume | 83,965 |
| Avg. Volume (20D) | 2,285,220 |
| Open | 1.04 |
| Previous Close | 1.04 |
| Day's Range | 0.95 - 1.04 |
| 52-Week Range | 0.91 - 7.20 |
| Beta | 0.84 |
About SLRX
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategi...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 29, 2015
Employees 2
Stock Exchange NASDAQ
Ticker Symbol SLRX
Website https://www.salariuspharma.com
1 month ago
+133.76%
Salarius Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
11 months ago
+5.98%
Salarius Pharmaceuticals shares are trading higher after the company reported Q4 financial results.
